Post-earnings recap
Reported
Tue, Feb 18, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is still in a challenging phase, as reflected by the stock's 2.54% decline. Investors may be concerned about the lack of revenue data and guidance, which could signal uncertainty about future performance. Management's focus on R&D and customer relationships suggests they are looking to strengthen their position in the market despite current hurdles.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.07 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a cautious optimism about future growth despite current challenges. They are focusing on innovation and customer engagement.
Management highlighted ongoing investments in R&D to drive future growth.
They emphasized the importance of maintaining strong customer relationships.
Management noted challenges in the current market environment.